Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BeOne Medicines's Accounts Payable for the quarter that ended in Mar. 2026 was R$2,215 Mil.
BeOne Medicines's quarterly Accounts Payable
increased
from Sep. 2025 (R$2,058 Mil) to Dec. 2025 (R$2,613 Mil) but then
declined
from Dec. 2025 (R$2,613 Mil) to Mar. 2026 (R$2,215 Mil).
BeOne Medicines's annual Accounts Payable
increased
from Dec. 2023 (R$1,544 Mil) to Dec. 2024 (R$2,471 Mil) and
increased
from Dec. 2024 (R$2,471 Mil) to Dec. 2025 (R$2,613 Mil).
BeOne Medicines Accounts Payable Related Terms
BeOne Medicines Accounts Payable Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's Accounts Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.
BeOne Medicines (BSP:B1ME34) has a Accounts Payable of R$2,215 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on BeOne Medicines and its competitors.
Is BeOne Medicines' Accounts Payable too high?
BeOne Medicines' current Accounts Payable is R$2,215 Mil. Overall, BeOne Medicines has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Accounts Payable compare to ALNY and RVMD?
BeOne Medicines' Accounts Payable of R$2,215 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current Accounts Payable is R$2,215 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
BeOne Medicines (BSP:B1ME34) has a current Accounts Payable of R$2,215 Mil. The stock's GF Value™ is R$72.75, compared to a current price of R$64.68 — trading 11.1% below its estimated fair value. The current Accounts Payable is R$2,215 Mil. BeOne Medicines' overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For BeOne Medicines (BSP:B1ME34), the current Accounts Payable is R$2,215 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (BSP:B1ME34) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of R$64.68 is trading 11.1% below its estimated GF Value™ of R$72.75.
Key valuation signals for BSP:B1ME34:
Accounts Payable: R$2,215 Mil
GF Value™: R$72.75 vs. price of R$64.68 (11.1% below fair value)
No single metric tells the full story. See the BSP:B1ME34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
77GF Score
Get the complete analysis for BSP:B1ME34
Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:B1ME34 has been successfully added to your 
